Acceleration of BRAFV600E-induced thyroid carcinogenesis by TGFβ signal deficiency in mice
- 12 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Endocrine
- Vol. 69 (3), 571-577
- https://doi.org/10.1007/s12020-020-02298-1
Abstract
Purpose Transforming growth factor-β (TGFβ) has pleiotropic actions, including both anti- and pro-tumorigenic abilities. We have previously shown no tumor development in the thyroid-specific TGFβ receptor type II knockout (Tgfβr2 KO) mice, indicating the insufficiency of defective TGFβ signal itself for thyroid cancer initiation. In the current study, we evaluated whether defective TGFβ signal accelerates BRAFV600E-mediated thyroid carcinogenesis in our mouse model, in which intrathyroidal injection of adenovirus expressing Cre under thyroglobulin (TG) promoter (Ad-TgP-Cre) into thyroid lobes of conditional BrafV600E knock-in mice (BrafCA) induces thyroid cancers 12 months later. Methods BrafCA/wt;Tgfbr2floxE2/floxE2 mice were generated by crossing Tgfbr2floxE2/floxE2 and BrafCA mice, and Ad-TgP-Cre was injected into the left lobes of 4–6-week-old mice. Mice were sacrificed at 6 and 12 months, and the thyroid tissues were subjected to H&E and immune-histochemistry and -fluorecence. Results Thyroid tumors were observed in 8 of 10 mice at 6 months and 4 of 7 mice at 12 months. These tumors were judged to be malignant by H&E staining, because of the presence of papillary growth of atypical follicular cells, intranuclear cytoplasmic inclusions and so on. Immunohistochemical analyses using thyroid cancer tissues obtained at 6 months demonstrated variable levels of TG but steady levels of Paired Box-8 expression and higher Ki67 positivity. The degree of epithelial-to-mesenchymal transition could not be evaluated because normal thyroid tissues and thyroid cancers developed in BrafCA and BrafCA/wt;Tgfbr2floxE2/floxE2 mice were all E-cadherin+/vimentin−, that is, epithelial type. Conclusion In a mouse model, defective TGFβ signaling pathway accelerates BRAFV600E-induced thyroid cancer development, which is occasionally accompanied by reduced TG expression implying dedifferentiation. The former finding is consistent with anti-tumorigenic ability of TGFβ in early tumorigenic process, but the latter is contradictory to generally accepted concept for TGFβ-induction of dedifferentiation.Funding Information
- Kato Memorial Bioscience Foundation
This publication has 34 references indexed in Scilit:
- Mouse models of sporadic thyroid cancer derived from BRAFV600E alone or in combination with PTEN haploinsufficiency under physiologic TSH levelsPLOS ONE, 2018
- Targeting Transforming Growth Factor-Beta1 (TGF-β1) Inhibits Tumorigenesis of Anaplastic Thyroid Carcinoma Cells Through ERK1/2-NFκkB-PUMA SignalingMedical Science Monitor, 2016
- The changing epidemiology of thyroid cancerCurrent Opinion in Oncology, 2015
- Integrated Genomic Characterization of Papillary Thyroid CarcinomaCell, 2014
- Disruption of transforming growth factor-β signaling in thyroid follicular epithelial cells or intrathyroidal fibroblasts does not promote thyroid carcinogenesisEndocrine Journal, 2014
- Role of Transforming Growth Factor Beta in the Regulation of Thyroid Function and GrowthThyroid®, 2009
- Transforming Growth Factor β1Selectively Inhibits the Cyclic AMP-dependent Proliferation of Primary Thyroid Epithelial Cells by Preventing the Association of Cyclin D3–cdk4 with Nuclear p27kip1Molecular Biology of the Cell, 2000
- Expression of Transforming Growth Factor-β1, Activin A, and Their Receptors in Thyroid Follicle Cells: Negative Regulation of Thyrocyte Growth and Function1Endocrinology, 1999
- TGF-β1 actions on FRTL-5 cells provide a model for the physiological regulation of thyroid growthOncogene, 1998
- General inhibition by transforming growth factor β1 of thyrotropin and cAMP responses in human thyroid cells in primary cultureMolecular and Cellular Endocrinology, 1993